Despite Genotyping Growth, Affymetrix's Q3 Sales Fall 5 Percent on Service Slowdown

While Affy officials said they were "surprised" by the decrease in service revenues, they cited "steady progress" in the company's genotyping and expression businesses.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.